Ischemic Stroke - Pipeline Review, H2 2015 Summary Global Markets Direct s, Ischemic Stroke - Pipeline Review, H2 2015, provides an overview of the Ischemic Strokes therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Ischemic Stroke - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ischemic Stroke and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ischemic Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ischemic Stroke pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ischemic Stroke - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ischemic Stroke pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Browse Complete Report with TOC @http://www.idatainsights.com/reports-landing-page.php?id=124188/ischemic-stroke-pipeline-review-h2-2015
To Get Sample Copy of Report visit @http://www.idatainsights.com/reports-landing-page.php?id=124188/ischemic-stroke-pipeline-review-h2-2015
Table of Contents
Table of Contents
2 List of Tables
6 List of Figures
9 Global Markets Direct Report Coverage
9 Ischemic Stroke Overview
10 Therapeutics Development
11 Pipeline Products for Ischemic Stroke - Overview
11 Pipeline Products for Ischemic Stroke - Comparative Analysis 12 Ischemic Stroke - Therapeutics under Development by Companies
13 Ischemic Stroke - Therapeutics under Investigation by Universities/Institutes 18 Ischemic Stroke - Pipeline Products Glance
19 Late Stage Products
19 Clinical Stage Products
20 Early Stage Products
21 Ischemic Stroke - Products under Development by Companies
22 Ischemic Stroke - Products under Investigation by Universities/Institutes
27 Ischemic Stroke - Companies Involved in Therapeutics Development
28 AB Science SA
28 Acticor Biotech
29 advanceCor GmbH
30 Angion Biomedica Corp.
31 AstraZeneca Plc
32 Athersys, Inc.
33 biOasis Technologies Inc.
34 Biogen, Inc.
35 BioTime, Inc.
36 D-Pharm Ltd. 37 Daiichi Sankyo Company, Limited 38 DiaMedica Inc.
39 Digna Biotech, S.L. 40 Genervon Biopharmaceuticals, LLC
41 Glialogix, Inc.
42 Glucox Biotech AB
43 Grifols, S.A.
44 Huons Co., Ltd.
45 International Stem Cell Corporation
46 JN-International Medical Corporation 47 Laboratoires Pierre Fabre SA
48 Lumosa Therapeutics Co., Ltd.
49 MediaPharma s.r.l.
50 Mitsubishi Tanabe Pharma Corporation
51 Neuralstem, Inc.
52 Neurotec Pharma SL
53 NeuroVive Pharmaceutical AB
54 NoNO, Inc.
55 Panacea Pharmaceuticals, Inc.
56 Pharmicell Co., Ltd.
57 PhytoHealth Corporation
58 Remedy Pharmaceuticals, Inc.
59 ReNeuron Group Plc
60 SanBio, Inc.
61 Saneron CCEL Therapeutics, Inc.
62 Simcere Pharmaceutical Group
63 Stemedica Cell Technologies, Inc.
64 SynZyme Technologies, LLC
65 The International Biotechnology Center (IBC) Generium
66 TikoMed AB
67 vasopharm GmbH 68 Vicore Pharma AB
69 Virogenomics, Inc.
70 Ischemic Stroke - Therapeutics Assessment
71 Assessment by Monotherapy Products
71 Assessment by Target
72 Assessment by Mechanism of Action
76 Assessment by Route of Administration
79 Assessment by Molecule Type
81 Drug Profiles
83 3K3A-APC - Drug Profile
83 ACT-017 - Drug Profile
85 alteplase biosimilar - Drug Profile
86 BB-3 - Drug Profile
87 BSc-2118 - Drug Profile
90 C-21 - Drug Profile
91 Cerecellgram-Stroke - Drug Profile
93 CNB-001 - Drug Profile
94 DB-017 - Drug Profile
96 DM-199 - Drug Profile
97 Drugs to Inhibit Sir2 Protein for Ischemic Stroke and Myocardial Infarction - Drug Profile
98 DS-1040 - Drug Profile
99 GLX-1112 - Drug Profile
100 glyburide - Drug Profile
101 GM-602 - Drug Profile
103 GXNPC-1 - Drug Profile
104 HBN-1 - Drug Profile
105 HU-010 - Drug Profile
106 Human Plasmin - Drug Profile
107 Human Umbilical Cord Blood Cell Therapy for Neurological and Cardiovascular Diseases - Drug Profile
109 ISC-hpNSC - Drug Profile
112 levomilnacipran hydrochloride ER - Drug Profile
114 LT-3001 - Drug Profile
116 Lysimab - Drug Profile
117 masitinib - Drug Profile
118 Memantine Nitrone - Drug Profile
123 Mesenchymal Stem Cells - Drug Profile 124 MP-
124 - Drug Profile 126 MPHE-001A - Drug Profile
127 MTfp-siRNA - Drug Profile 128 MultiStem - Drug Profile
129 NA-1 - Drug Profile
133 natalizumab - Drug Profile
135 NSI-566 - Drug Profile
137 NTKC-005 - Drug Profile
139 NVP-014 - Drug Profile
140 NVX-208 - Drug Profile
141 PAN-811 - Drug Profile
142 Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - Drug Profile
144 PHN-014 - Drug Profile
146 Pinocembrin - Drug Profile
370 for Ischemic Stroke - Drug Profile
148 PR-15 - Drug Profile
149 prasugrel hydrochloride - Drug Profile
151 Protein for Ischemic Stroke - Drug Profile
154 Protein for Ischemic Stroke - Drug Profile
155 Protein for Ischemic Stroke - Drug Profile
156 Recombinant Peptide for Ischemic Stroke - Drug Profile
157 Recombinant Plasmin - Drug Profile
159 Recombinant Protein for Ischemic Cerebral Stroke and Myocardial Ischemia - Drug Profile
160 Recombinant Proteins to Inhibit Serine Protease for Thrombosis, Ischemic Stroke and Atherosclerosis - Drug Profile
161 ReN-001 - Drug Profile
162 RTL-551 - Drug Profile
164 SB-623 - Drug Profile
166 SIM-071201 - Drug Profile
168 Small Molecule to Activate Epsilon PKC for Ischemic Stroke - Drug Profile
169 Small Molecule to Block Sodium Channels for Ischemic Stroke - Drug Profile
170 Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile
171 Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile
172 Small Molecules to Activate Glutathione Peroxidase for Ischemic Stroke and Liver Failure - Drug Profile
173 Small Molecules to Block Sodium and hERG Channel for Ischemic Stroke - Drug Profile
174 Small Molecules to Inhibit CaMKII for Ischemic Stroke - Drug Profile
175 Small Molecules to Inhibit Kinase for Ischemic Stroke - Drug Profile
176 SMTP-7 - Drug Profile 177 StromAb - Drug Profile
178 T-33 - Drug Profile
180 TF-0023 - Drug Profile
181 THR-18 - Drug Profile
182 ticagrelor - Drug Profile
183 TM-700 - Drug Profile
187 TPAi-14 - Drug Profile
188 TPAi-23 - Drug Profile
189 TS-01 - Drug Profile
190 TXA-127 - Drug Profile
191 TXA-302 - Drug Profile
193 UCCB-01144 - Drug Profile
195 Vaccine to Target NMDAR1 for Ischemic Stroke - Drug Profile
196 VACNO - Drug Profile
197 VAS-2870 - Drug Profile
198 Ischemic Stroke - Recent Pipeline Updates
199 Ischemic Stroke - Dormant Projects
255 Ischemic Stroke - Discontinued Products
260 Ischemic Stroke - Product Development Milestones
263 Featured News & Press Releases
270 Secondary Research
270 Primary Research
270 Expert Panel Validation
270 Contact Us
iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.
We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects.